4 results match your criteria: "Toulouse-Oncopole University Cancer Institute (IUCT-O)[Affiliation]"
Efficacy of a short sandwich protocol, methotrexate, gemcitabine, L-asparaginase and dexamethasone chemotherapy combined with radiotherapy, in localised newly diagnosed NK/T-cell lymphoma: A French retrospective study.
Br J Haematol
May 2023
Hematology Department, Limoges University Hospital, Limoges, France.
Article Synopsis
- Extranodal NK/T-cell lymphoma, nasal type is a rare and aggressive cancer with a traditionally poor outlook, but a study explored a new treatment combining MGAD chemotherapy with targeted radiotherapy.
- In this study of 35 newly diagnosed patients, 91% achieved complete remission, with promising long-term survival rates of 71% at 2 years and 53% at 5 years.
- While some patients faced manageable side effects and a third relapsed within about 14.5 months, the short treatment approach showed effectiveness and tolerability for this challenging condition.
Low incidence of mutations in idiopathic erythrocytosis.
Haematologica
January 2021
Pole Biologie, Laboratory of Excellence GR-Ex, Université de Bourgogne, Dijon.
Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia.
BMC Cancer
August 2019
Department of Haematology, Toulouse-Oncopole University Cancer Institute (IUCT-O), 1 Avenue Irene Joliot-Curie, 31059, Toulouse, France.
Background: Eradication of minimal residual disease (MRD), at the end of Fludarabine-Cyclophosphamide-Rituximab (FCR) treatment, is a validated surrogate marker for progression-free and overall survival in chronic lymphocytic leukaemia. But such deep responses are also associated with severe immuno-depletion, leading to infections and the development of secondary cancers.
Methods: We assessed, blood MRD and normal immune cell levels at the end of treatment, in 162 first-line FCR patients, and analysed survival and adverse event.
Delivering of > 80% planned relative dose intensity (RDI) of fludarabine-cyclophosphamide-rituximab (FCR) is key to benefit from longer progression free survival (PFS) and survivals in CLL. In this randomized trial, we sought to investigate whether a telephone intervention strategy (called AMA) delivered by an oncology nurse could reduce the risk of RDI < 80% by alleviating adverse events and supporting patients' adherence. Sixty FCR patients were randomized 1:1 for AMA (stratified on Binet stage C).
View Article and Find Full Text PDF